Breakthrough technology transforms months-long market access analysis into minutes.
LONDON, UK — 1st September 2025, – Access Infinity today announced the launch of its groundbreaking AI-powered price and HTA (Health Technology Assessment) predictions feature, now available on Nuro, the company’s market access insights platform. This innovative capability represents a major evolution for Early Market Access teams, reducing complex drug pricing and HTA outcome analysis from months to minutes.
The new feature addresses a critical pain point in pharmaceutical market access, where teams traditionally spend extensive time analysing complex datasets to predict drug pricing strategies and HTA outcomes. By harnessing advanced artificial intelligence, Nuro now transforms intricate drug parameters into clear, actionable insights that enable market access leaders to accelerate their strategies, reduce uncertainty, and make more informed pricing decisions.
“In the last 12 months in particular, we’ve seen many Market Access teams make the leap from exploring how they can adopt AI to embracing AI by integrating it into their everyday processes,” said Tom Gilboy, Product Owner at Access Infinity.
The AI-powered predictions feature builds on Nuro’s existing capabilities as the ultimate AI-powered insights tool for market access and pricing teams. The platform already helps organisations overcome common challenges including complex data sourcing, tight delivery timescales, and the high costs associated with using external consultancies. With this new functionality, users can now access sophisticated price and HTA predictions alongside Nuro’s established features for analogue analysis, competitor benchmarking, and deep HTA insights.
Access Infinity continues to lead the way in AI adoption within market access, value and pricing, pioneering innovative solutions that transform how pharmaceutical companies approach pricing and market access strategies. “This new feature exemplifies our commitment to pushing the boundaries of what’s possible in pharmaceutical market access intelligence,” said Keshav Nagaraja, Managing Director – Digital at Access Infinity.
The company’s commitment to advancing AI integration within market access and HEOR processes positions the company at the forefront of digital transformation, consistently delivering innovations that address real-world challenges faced by these teams.
The new AI-powered price and HTA predictions feature is now available to all Nuro users. For organisations seeking to modernise their market access capabilities and reduce reliance on time-intensive manual analysis, this advancement represents a significant opportunity to enhance strategic decision-making while optimising resource allocation.
Related resources:
For more information about Nuro, please visit: accessinfinity.com/nuro
To see Nuro in action, get in touch here.
You can also sign up for our upcoming webinar ‘AI-powered Price & HTA Predictions: Live Nuro Demo’ on Thursday 2nd October here.
Founded in 2014, Access Infinity helps pharmaceutical companies launch and price their products more effectively by combining deep strategic consulting expertise with digital platforms purpose-built for market access and HEOR teams. The company’s experienced consultants work closely with global through to local teams to shape launch strategies, optimise pricing and access, and navigate complex policy landscapes.
Access Infinity’s core digital solutions – Access Hub, Evidence Hub and Nuro – streamline everything from launch tracking and evidence planning to pricing strategy, enabling faster, smarter, and more coordinated decision-making across the product lifecycle. With offices in London, Manchester and Hyderabad, Access Infinity’s clients include many of the pharmaceutical industry’s most influential companies including AstraZeneca, GSK, J&J, MSD, and Pfizer.
For media enquiries, please contact:
Email: louise@accessinfinity.com
Tel: +44 (0)20 4583 5450
